Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology
- PMID: 35380226
- DOI: 10.1007/s00330-022-08732-4
Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology
Abstract
Background and aims: Transarterial 90Y radioembolization (TARE) is increasingly being used for hepatocellular carcinoma (HCC) treatment. However, tumor response assessment after TARE may be challenging. We aimed to assess the diagnostic performance of gadoxetate disodium MRI for predicting complete pathologic necrosis (CPN) of HCC treated with TARE, using histopathology as the reference standard.
Methods: This retrospective study included 48 patients (M/F: 36/12, mean age: 62 years) with HCC treated by TARE followed by surgery with gadoxetate disodium MRI within 90 days of surgery. Two radiologists evaluated tumor response using RECIST1.1, mRECIST, EASL, and LI-RADS-TR criteria and evaluated the percentage of necrosis on subtraction during late arterial, portal venous, and hepatobiliary phases (AP/PVP/HBP). Statistical analysis included inter-reader agreement, correlation between radiologic and pathologic percentage of necrosis, and prediction of CPN using logistic regression and ROC analyses.
Results: Histopathology demonstrated 71 HCCs (2.8 ± 1.7 cm, range: 0.5-7.5 cm) including 42 with CPN, 22 with partial necrosis, and 7 without necrosis. EASL and percentage of tumor necrosis on subtraction at the AP/PVP were independent predictors of CPN (p = 0.02-0.03). Percentage of necrosis, mRECIST, EASL, and LI-RADS-TR had fair to good performance for diagnosing CPN (AUCs: 0.78 - 0.83), with a significant difference between subtraction and LI-RADS-TR for reader 2, and in specificity between subtraction and other criteria for both readers (p-range: 0.01-0.04). Radiologic percentage of necrosis was significantly correlated to histopathologic degree of tumor necrosis (r = 0.66 - 0.8, p < 0.001).
Conclusions: Percentage of tumor necrosis on subtraction and EASL criteria were significant independent predictors of CPN in HCC treated with TARE. Image subtraction should be considered for assessing HCC response to TARE when using MRI.
Key points: • Percentage of tumor necrosis on image subtraction and EASL criteria are significant independent predictors of complete pathologic necrosis in hepatocellular carcinoma treated with90Y radioembolization. • Subtraction, mRECIST, EASL, and LI-RADS-TR have fair to good performance for diagnosing complete pathologic necrosis in hepatocellular carcinoma treated with90Y radioembolization.
Keywords: Embolization; Gadoxetate disodium; Hepatocellular carcinoma; Magnetic resonance imaging; Yttrium radioisotopes.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.
Similar articles
-
Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.J Hepatol. 2017 Dec;67(6):1213-1221. doi: 10.1016/j.jhep.2017.07.030. Epub 2017 Aug 18. J Hepatol. 2017. PMID: 28823713
-
Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.Abdom Radiol (NY). 2018 Jul;43(7):1825-1836. doi: 10.1007/s00261-017-1354-6. Abdom Radiol (NY). 2018. PMID: 29052747
-
Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes.Eur J Radiol. 2020 Dec;133:109351. doi: 10.1016/j.ejrad.2020.109351. Epub 2020 Oct 14. Eur J Radiol. 2020. PMID: 33096408
-
Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: a systematic review and meta-analysis.Eur Radiol. 2022 Aug;32(8):5134-5143. doi: 10.1007/s00330-022-08665-y. Epub 2022 Mar 10. Eur Radiol. 2022. PMID: 35267090 Review.
-
Imaging of Hepatocellular Carcinoma Response After 90Y Radioembolization.AJR Am J Roentgenol. 2017 Nov;209(5):W263-W276. doi: 10.2214/AJR.17.17993. AJR Am J Roentgenol. 2017. PMID: 29072955 Review.
Cited by
-
Early post-treatment MRI predicts long-term hepatocellular carcinoma response to radiation segmentectomy.Eur Radiol. 2024 Jan;34(1):475-484. doi: 10.1007/s00330-023-10045-z. Epub 2023 Aug 4. Eur Radiol. 2024. PMID: 37540318 Free PMC article.
-
Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI.J Magn Reson Imaging. 2023 Jun;57(6):1641-1654. doi: 10.1002/jmri.28659. Epub 2023 Mar 5. J Magn Reson Imaging. 2023. PMID: 36872608 Free PMC article. Review.
References
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108 - DOI
-
- Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30:61–74 - DOI
-
- Galun D, Basaric D, Zuvela M et al (2015) Hepatocellular carcinoma: from clinical practice to evidence-based treatment protocols. World J Hepatol 7:2274–2291 - DOI
-
- Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW (2013) Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 19:7515–7530 - DOI
-
- Gabr A, Abouchaleh N, Ali R et al (2018) Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol 29:1502–1510 e1501 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous